Avalo Therapeutics to present Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa at EADV 2026

AVTX•2026-09-23

Upcoming Phase 2 LOTUS presentations

Avalo Therapeutics flagged new Phase 2 LOTUS trial results for abdakibart in moderate-to-severe hidradenitis suppurativa at EADV 2026.

Results have not been presented yet; a poster is scheduled for Sept. 30, 2026, followed by a late-breaker oral talk on Oct. 1.

The presentations are set to highlight efficacy and safety outcomes, including subgroup and lesion-type analyses, without disclosing new numerical detail in the announcement.

Abdakibart is positioned as a selective anti-IL-1β antibody, supporting the company’s strategy in immune-mediated inflammatory diseases.

Avalo Therapeutics to present Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa at EADV 2026

Upcoming Phase 2 LOTUS presentations

Related News

Jefferies resumes coverage of Aevex with 'buy' rating after BlackSea acquisition

First BanCorp schedules third-quarter earnings release and investor call

BofA forecasts two BoE rate hikes as energy prices stoke inflation concerns

Morning News Call - U.S., September 23

AIRO invited to Drone Dominance Program Phase 2.5 bomber qualifier